PSNL logo

PSNL
Personalis Inc

2,776
Mkt Cap
$688.48M
Volume
978,069.00
52W High
$11.50
52W Low
$2.83
PE Ratio
-7.24
PSNL Fundamentals
Price
$6.58
Prev Close
$6.56
Open
$6.19
50D MA
$8.24
Beta
2.18
Avg. Volume
1.69M
EPS (Annual)
-$0.9107
P/B
2.58
Rev/Employee
$267,876.92
$511.21
Loading...
Loading...
News
all
press releases
Personalis to Participate in the 25th Annual Needham Virtual Conference
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will be participating in the 25th Annual Needham Virtual Conference on...
Business Wire·3d ago
News Placeholder
More News
News Placeholder
Personalis (NASDAQ:PSNL) Trading Down 9.3% - Should You Sell?
Personalis (NASDAQ:PSNL) Trading Down 9.3% - Time to Sell...
MarketBeat·9d ago
News Placeholder
229,435 Shares in Personalis, Inc. $PSNL Bought by Oracle Investment Management Inc.
Oracle Investment Management Inc. bought a new stake in Personalis, Inc. (NASDAQ:PSNL - Free Report) during the third quarter, according to the company in its most recent filing with the Securities...
MarketBeat·18d ago
News Placeholder
Personalis Appoints Dr. Richard Chen as President to Further Accelerate MRD Adoption
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced the promotion of Richard Chen, M.D., M.S., to the position of President. Dr. Chen will continue...
Business Wire·18d ago
News Placeholder
Personalis (NASDAQ:PSNL) Trading 6.6% Higher - Time to Buy?
Personalis (NASDAQ:PSNL) Shares Up 6.6% - Should You Buy...
MarketBeat·23d ago
News Placeholder
Personalis (NASDAQ:PSNL) Stock Price Down 8.1% - What's Next?
Personalis (NASDAQ:PSNL) Trading Down 8.1% - Should You Sell...
MarketBeat·24d ago
News Placeholder
Personalis Announces New Publication Advancing Neoadjuvant Treatment Monitoring in Breast Cancer with NeXT Personal
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced the publication of the PREDICT-DNA study in the Journal of Clinical Oncology. The article, 'The...
Business Wire·24d ago
News Placeholder
Personalis, Inc. (NASDAQ:PSNL) Receives Average Recommendation of "Moderate Buy" from Analysts
Personalis, Inc. (NASDAQ:PSNL - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the eight research firms that are currently covering the stock, Marketbeat Ratings...
MarketBeat·25d ago
News Placeholder
Personalis (NASDAQ:PSNL) Rating Increased to Hold at Wall Street Zen
Wall Street Zen raised Personalis from a "sell" rating to a "hold" rating in a research report on Sunday...
MarketBeat·28d ago
News Placeholder
Morgan Stanley Has Lowered Expectations for Personalis (NASDAQ:PSNL) Stock Price
Morgan Stanley decreased their target price on shares of Personalis from $11.00 to $10.00 and set an "equal weight" rating for the company in a research note on Thursday...
MarketBeat·1mo ago
<
1
2
...
>

Latest PSNL News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.